PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 14664029

A contextual coding system for transplantation and end stage diseases.

Christian Jacquelinet·Anita Burgun·Sami Djabbour·Denis Delamarre·Patrick Clerc·Bernard Boutin·Pierre Le Beux
View original source ↗Export metadata ↓

Abstract

The Establissement français des Greffes (EfG) is a state agency dealing with Public Health issues related to organ, tissue and cell transplantation in France. EfG maintains a national information system (EfG-IS) for the evaluation of organ transplantation activities. The EfG-IS is moving toward a new n-tier architecture comprising a terminological server. Because this terminological server is shared by various kind of transplant teams and dialysis centers to record patients data at different time point, contextualisation of terms appeared as a functional requirement. We report in this paper various contexts for medical terms and how they have been taken into account.

Explore related subjects

Cell TransplantationComputer SystemsForms and Records ControlFranceGovernment AgenciesHumansInformation SystemsTerminally IllTissue TransplantationTransplantationJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Christian Jacquelinet, Anita Burgun, Sami Djabbour, Denis Delamarre, Patrick Clerc, Bernard Boutin, Pierre Le Beux. 2003. A contextual coding system for transplantation and end stage diseases.. https://pubmed.ncbi.nlm.nih.gov/14664029/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Cell-based gene therapy for the prevention and treatment of cardiac dysfunction.

A substantial need exists for new treatments to prevent and treat cardiac dysfunction. In the 1990s, there was great hope for gene therapy in this regard. Since that time, the focus has switched to cell therapy-in particular, therapy-with the aim of inducing myocardial regeneration. Individually, gene and cell therapies still have substantial promise. Ultimately, however, the convergence of both techniques might be necessary to achieve improvements in cardiac function and more successful clinical outcomes in patients with cardiac dysfunction. This approach has already been adopted for treatment of malignancies. Several gene products are currently being studied, including growth factors and chemokines that can modulate the survival and function of cardiac myocytes following an ischemic event and influence remodeling of the left ventricle. However, several issues remain, including the optimization and characterization of cell types, selection of vectors for gene transfer, and identification of appropriate strategies for delivery. Here, we review the potential and need for cell-based gene therapy for the prevention and treatment of cardiac dysfunction and attempt to discuss the unresolved issues.

Cell Transplantation↗
PubMed2006

Present status and perspectives of cell-based therapies for liver diseases.

In recent years the interest in liver cell therapy has been increasing continuously, since the demand for whole liver transplantations in human beings far outweighs the supply. From the clinical point of view, transplantation of hepatocytes or hepatocyte-like cells may represent an alternative to orthotopic liver transplants in acute liver failure, for the correction of genetic disorders resulting in metabolically deficient states, and for late stage liver disease such as cirrhosis. Although the concept of cell therapy for various diseases of the liver is widely accepted, the practical approach in humans often remains difficult. An international expert panel critically discussed the recent published data on clinical and experimental hepatocyte transplantation and the possible role of stem cells in liver tissue repair. This paper aims to summarise the present status of cell based therapies for liver diseases and to identify areas of future preclinical and clinical research.

Cell Transplantation↗